Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

2/22/2024
GlaucomaMeetingNewsletter
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease

Innovative diagnostics for glaucoma screening, staging, and management were a highlight of the Glaucoma 360 New Horizons Forum, with several physicians showcasing new approaches to visual field tes...

2/22/2024
AcquisitionsDeviceNewsletterRetinaSurgical
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition

Carl Zeiss Meditec’s acquisition of DORC (Dutch Ophthalmic Research Center) will change the players in the retinal surgical equipment market, but whether it will lead to any major changes in market...

2/22/2024
LaserNewsletterRefractive
Bausch + Lomb Teneo Excimer Laser Enters US Market After Drought in New Technology
Bausch + Lomb Teneo Excimer Laser Enters US Market After Drought in New Technology

A new excimer laser has entered the US refractive market for the first time in nearly two decades. Bausch + Lomb announced in January that the US FDA had approved the Teneo excimer laser platform f...

2/22/2024
AcquisitionsDealsNewsletterRetina
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front

Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...

2/22/2024
ChinaDry EyeIndustryNewsletter
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets

Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...

2/22/2024
NewsletterRegulation
US FDA Warns of Contamination Risk with Copycat Lumify Eye Drops
US FDA Warns of Contamination Risk with Copycat Lumify Eye Drops

The US FDA issued a warning Jan. 31 to consumers not to purchase or use South Moon, Rebright, or FivFivGo eye drops because of the potential risk of eye infection. The products are copycats that ca...

2/22/2024
IndiaNewsletterRegulation
India Orders Tougher Drug-Making Standards After Overseas Deaths
India Orders Tougher Drug-Making Standards After Overseas Deaths

Prime Minister Narendra Modi’s government has stepped up scrutiny of India’s pharmaceutical factories after being stung by a series of overseas deaths linked to Indian-made drugs. The news agency R...

2/22/2024
GlaucomaLaserNewsletterRefractiveRegulation
Select US FDA Approvals and Clearances in January 2024
Select US FDA Approvals and Clearances in January 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in January 2024, according to the agency’s database. Meridian received clearance for three laser mo...

2/22/2024
NewsletterRegulation
CMS is Implementing Time Limit on Prior Authorization Decisions
CMS is Implementing Time Limit on Prior Authorization Decisions

The Centers for Medicare and Medicaid Services (CMS) issued a final rule on Jan. 17 that will limit the amount of time for certain payers to make prior authorization decisions. Payers will have 72 ...

2/22/2024
Clinical TrialNewsletterRegulation
Japan Eases Clinical Trial Requirements for Foreign Drugmakers in Growing Trend
Japan Eases Clinical Trial Requirements for Foreign Drugmakers in Growing Trend

Japan has removed the requirement that foreign drugmakers conduct a Phase I clinical trial in Japan before Japanese individuals participate in Phase III multiregional clinical trials (MRCT) for reg...

2/22/2024
DealsFundingGene TherapyGlaucomaNewsletterRetinaSurgical
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

2/22/2024
GlaucomaMeetingNewsletterSurvey
Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High
Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High

Ophthalmologist (MD) and optometrist (OD) attendees of the 2024 Glaucoma 360 (G360) meeting demonstrated a record interest in participating in the Ninth Annual G360 Survey powered by Market Scope. ...

Past News Stories

2/22/2024
GlaucomaMeetingNewsletterSurgical
Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum
Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum

Two of ophthalmology’s leading innovators headlined the New Horizons Forum at the Glaucoma 360 meeting. Sean Ianchulev, MD—arguably the most prolific ophthalmic product inventor in the US—led off t...

2/22/2024
GlaucomaMeetingNewsletterRegulation
Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say
Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say

Attendees of the G360 New Horizons Forum received a detailed breakdown of the battle that the ophthalmic industry collectively waged throughout 2023 to stop proposed limits to Medicare coverage for...

2/22/2024
CataractNewsletterRegulationSurgical
MAC Drops Plan to Require Visual Acuity of 20/50 or Worse for Cataract Surgery
MAC Drops Plan to Require Visual Acuity of 20/50 or Worse for Cataract Surgery

Wisconsin Physician Services (WPS), a Medicare Administrative Contractor (MAC) in the US, has abandoned a proposal to require visual acuity of 20/50 or worse for cataract surgery to be medically ne...

2/22/2024
Clinical TrialDry EyeNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates
Clinical Trial Updates for Ophthalmic Candidates

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

2/22/2024
IndustryNewsletterRegulation
Eyenovia Announces US FDA Clearance of Manufacturing Facility in California
Eyenovia Announces US FDA Clearance of Manufacturing Facility in California

Eyenovia, of New York, announced Feb. 13 that the company’s facility in Redwood City, California, had successfully completed US FDA inspection for approval as a commercial manufacturing facility. T...

2/22/2024
EuropeNewsletterRegulationRetina
Apellis Seeks Re-examination of EU Marketing Application for Pegcetacoplan in GA
Apellis Seeks Re-examination of EU Marketing Application for Pegcetacoplan in GA

Apellis Pharmaceuticals announced Jan. 26 that, as expected, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recom-mended refusal of the company’s marketin...

2/22/2024
NewsletterRetinaStudy
LambdaVision Sends 9th Artificial Retina Experiment to ISS
LambdaVision Sends 9th Artificial Retina Experiment to ISS

LambdaVision’s ninth planned space experiment launched Jan. 30 from Cape Canaveral for the International Space Station. LambdaVision, of Farmington, Connecticut, is trying to leverage microgravity ...

2/22/2024
CataractEuropeIOLNewsletterSurgical
Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in EMEA Countries
Johnson & Johnson MedTech Launches Tecnis PureSee PC-IOL in EMEA Countries

Johnson & Johnson MedTech announced Feb. 15 that its Tecnis PureSee refractive presbyopia-correcting intraocular lens (IOL) is now available in select markets in Europe, the Middle East, and Africa...

2/22/2024
Clinical TrialGene TherapyNewsletterRetina
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Wet AMD Trial
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Wet AMD Trial

4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...

2/22/2024
CornealFundingNewsletterStudy
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea

Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...

2/22/2024
CornealNewsletterStudy
Mass Eye and Ear Study Reveals that Neuropeptide Promotes Corneal Healing
Mass Eye and Ear Study Reveals that Neuropeptide Promotes Corneal Healing

A recent study by investigators at Mass Eye and Ear of the Harvard Medical School Department of Ophthalmology revealed that the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes cornea...

2/22/2024
GlaucomaNewsletter
Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84
Glaucoma Specialist H. Dunbar Hoskins Jr., MD, Dies at 84

Glaucoma specialist H. Dunbar Hoskins Jr., MD, a longtime executive of the American Academy of Ophthalmology who helped shape the society, died Jan. 27, the AAO reported. Hoskins was 84. He served ...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more